標(biāo)題: Titlebook: Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond; Aditi Bhatt Book 2018 Springer Nature Singapore Pte Ltd. 201 [打印本頁] 作者: Malinger 時(shí)間: 2025-3-21 17:14
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond影響因子(影響力)
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond影響因子(影響力)學(xué)科排名
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond網(wǎng)絡(luò)公開度
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond被引頻次
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond被引頻次學(xué)科排名
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond年度引用
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond年度引用學(xué)科排名
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond讀者反饋
書目名稱Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond讀者反饋學(xué)科排名
作者: Infraction 時(shí)間: 2025-3-21 22:08
Aditi BhattCovers all the recent developments in peritoneal surface oncology.Includes the basics of CRS and HIPEC like patient selection, surgical technique, HIPEC methodologies.Covers individual diseases with a作者: Etching 時(shí)間: 2025-3-22 01:58
http://image.papertrans.cn/m/image/622579.jpg作者: Constituent 時(shí)間: 2025-3-22 07:26
978-981-13-3910-3Springer Nature Singapore Pte Ltd. 2018作者: Foam-Cells 時(shí)間: 2025-3-22 09:16
Malignant Peritoneal MesotheliomaOne of the first descriptions of malignant peritoneal mesothelioma (MPM) was in a case report published 100 years ago [1]. In 1972, Moertel published a review of MPM and described the clinical presentation, histological features, and biological behavior of 169 patients [2].作者: 絕緣 時(shí)間: 2025-3-22 14:36 作者: Bureaucracy 時(shí)間: 2025-3-22 21:05
rgehen bei der Behandlung der Essst?rungen dar. .Neben umfangreichen online verfügbaren Arbeitsmaterialien finden sich in dem Manual ausführliche Anleitungen zu den einzelnen übungen und zahlreiche Fallbeispiel978-3-642-20384-8978-3-642-20385-5作者: Aerate 時(shí)間: 2025-3-22 23:57
Kayomarz Sethna,Shabber Zaveri,Aditi Bhattrgehen bei der Behandlung der Essst?rungen dar. .Neben umfangreichen online verfügbaren Arbeitsmaterialien finden sich in dem Manual ausführliche Anleitungen zu den einzelnen übungen und zahlreiche Fallbeispiel978-3-642-20384-8978-3-642-20385-5作者: 杠桿支點(diǎn) 時(shí)間: 2025-3-23 03:32
Arie Ariche,Dan Aderka,Almog Ben-Yaacov,Aviram Nissan Psychotherapeutinnen und -therapeuten und stellt praxisnah das konkrete therapeutische Vorgehen bei der Behandlung der Essst?rungen dar. .Neben umfangreichen online verfügbaren Arbeitsmaterialien finden sich in dem Manual ausführliche Anleitungen zu den einzelnen übungen und zahlreiche Fallbeispiel作者: judiciousness 時(shí)間: 2025-3-23 06:52 作者: 營(yíng)養(yǎng) 時(shí)間: 2025-3-23 10:39
Aditi Bhatt,Naoual Bakrin,Olivier Glehen Psychotherapeutinnen und -therapeuten und stellt praxisnah das konkrete therapeutische Vorgehen bei der Behandlung der Essst?rungen dar. .Neben umfangreichen online verfügbaren Arbeitsmaterialien finden sich in dem Manual ausführliche Anleitungen zu den einzelnen übungen und zahlreiche Fallbeispiel作者: Aesthete 時(shí)間: 2025-3-23 16:34
Aditi Bhatt,Sanket Mehta,Fran?ois Quénetman un- published manuscripts were omitted. The authors wish to thank Dr. Andreas Jaffe for the translation, and Evelyn Birke who typewrited the lecture-notes manuscrip~ ? . GUnzburg and Munich Sibylle Biefang November 1981 Wolfgang Kopcke Martin A. Schreiber Contents Page Foreword 1. Methods of The作者: nettle 時(shí)間: 2025-3-23 21:27
Aditi Bhatt,Guillaume Passot,Olivier Glehenman un- published manuscripts were omitted. The authors wish to thank Dr. Andreas Jaffe for the translation, and Evelyn Birke who typewrited the lecture-notes manuscrip~ ? . GUnzburg and Munich Sibylle Biefang November 1981 Wolfgang Kopcke Martin A. Schreiber Contents Page Foreword 1. Methods of The作者: 綠州 時(shí)間: 2025-3-23 22:15
Elizabeth Poli,Ashvin Rangole,Kiran K. Turagaice and use the SCIP psychopathology glossary as part of the emerging science of personalized medicine psychiatry (PMP)..Existing books on measures and rating scales, such as the two books above, describe different scales developed by different authors at different periods. Each scale has its own ra作者: 天氣 時(shí)間: 2025-3-24 03:47
Aditi Bhatt,Ramakrishnan Ayloor Seshadriice and use the SCIP psychopathology glossary as part of the emerging science of personalized medicine psychiatry (PMP)..Existing books on measures and rating scales, such as the two books above, describe different scales developed by different authors at different periods. Each scale has its own ra作者: 善辯 時(shí)間: 2025-3-24 06:37 作者: PLIC 時(shí)間: 2025-3-24 10:56 作者: 陶瓷 時(shí)間: 2025-3-24 18:51
Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond978-981-10-7053-2作者: 王得到 時(shí)間: 2025-3-24 19:59 作者: BLA 時(shí)間: 2025-3-24 23:50
Role of HIPEC in the Prevention of Peritoneal Metastasis from Colorectal, Gastric and Appendiceal Cabeen shown in a number of randomised studies from Asia and is also currently being evaluated in Western patients. The results of ongoing trials could well be a game changer in the prevention of colorectal and gastric cancer-associated peritoneal metastasis. Unlike colorectal and gastric cancer, muci作者: nocturia 時(shí)間: 2025-3-25 03:47
Diagnostic Laparoscopy for the Evaluation of Peritoneal MetastasesDVL) that allows direct visualization of the visceral and peritoneal surfaces is a useful adjunct to imaging modalities in selecting patients by predicting the extent of disease and the possibility of a complete cytoreduction. Though laparoscopy may be limited in some cases due to the presence of ad作者: choroid 時(shí)間: 2025-3-25 08:08 作者: tic-douloureux 時(shí)間: 2025-3-25 13:15
Management of Complications of CRS and HIPECcer which further emphasizes the importance of patient selection. It may result in a significant additional financial burden where such procedures are not under ‘insurance cover’ and are ‘out-of-pocket’ spending for patients. The 90-day morbidity and mortality capture the overall complication rate m作者: limber 時(shí)間: 2025-3-25 19:34 作者: Infraction 時(shí)間: 2025-3-25 21:58
Surgical Management of Recurrent Epithelial Ovarian Cancerse are the two most significant prognostic factors affecting the outcomes of CRS and HIPEC. With the availability of new chemotherapeutic agents and targeted therapies, treatment strategies, which integrate all these treatments to provide maximal gain in survival to patients while preserving the qua作者: 不能和解 時(shí)間: 2025-3-26 04:09
Multimodality Treatment for Colorectal Peritoneal Metastaseslivery like pressurized intraperitoneal aerosol chemotherapy (PIPAC) have shown promising results and are being evaluated prospectively. It is the patients with limited peritoneal disease that experience the maximum benefit from a curative approach; hence, the focus has shifted to the early detectio作者: BIDE 時(shí)間: 2025-3-26 06:20 作者: indoctrinate 時(shí)間: 2025-3-26 09:19
Intraperitoneal Chemotherapy for Gastric CancerPatients who have a good response can further undergo CRS and HIPEC. In the setting of metachronous gastric PM, pressurized intraperitoneal chemotherapy has produced good responses and is currently a prospective evaluation. Patients in the far east, i.e., Japan and China, have significantly better o作者: 嗎啡 時(shí)間: 2025-3-26 14:09 作者: pantomime 時(shí)間: 2025-3-26 20:38 作者: 秘密會(huì)議 時(shí)間: 2025-3-27 00:31
nique, HIPEC methodologies.Covers individual diseases with a.The widespread acceptance among the?oncology community at large of cytoreductive?surgery and HIPEC as a potentially?curative treatment for peritoneal metastases?has paved the way for innovative new therapies?that could benefit a larger pro作者: Mettle 時(shí)間: 2025-3-27 02:41
anaging peritoneal?metastases. The authors highlight essential?practical issues that surgical oncologists?encounter in their day-to-day practice, and?try to before provide evidence based answers?to address them. All chapters were written?and/or reviewed by leading experts in this?field..978-981-13-3910-3978-981-10-7053-2作者: Apraxia 時(shí)間: 2025-3-27 07:08
Cytoreductive Surgery for Peritoneal Metastases: Principles and Techniquesperiences of experts can guide surgeons on what to resect, how much, how, when, in whom, and how to manage the patient thereafter. A knowledge of the pathophysiology of peritoneal cancer spread forms the basis of providing this treatment and developing innovative therapies for future use.作者: BOLUS 時(shí)間: 2025-3-27 12:14
HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?. The aim of this manuscript is to review the rationale, variables, and modalities of intraperitoneal chemotherapy. At the same time, it seeks to offer guidance on the current intraperitoneal chemotherapy regimens and potential directions toward more standardization.作者: 荒唐 時(shí)間: 2025-3-27 15:46
Book 2018al?practical issues that surgical oncologists?encounter in their day-to-day practice, and?try to before provide evidence based answers?to address them. All chapters were written?and/or reviewed by leading experts in this?field..作者: 磨碎 時(shí)間: 2025-3-27 21:31 作者: 祖?zhèn)?nbsp; 時(shí)間: 2025-3-28 01:08
Book 2018 metastases?has paved the way for innovative new therapies?that could benefit a larger proportion of?patients. Much has been and continues to be?published on this subject..This book provides comprehensive reviews?on the various aspects of managing peritoneal?metastases. The authors highlight essenti作者: ablate 時(shí)間: 2025-3-28 05:01
Clinical Trials in CRS and HIPEC: Ongoing Trials and Future DirectivesC in metastatic gastric, ovarian, pancreatic, and other gastrointestinal malignancies has spurred further development of a growing number of prospective clinical trials to study outcomes and survival benefit. This chapter summarizes some of the notable, completed clinical trials and current trials being conducted.作者: CLOT 時(shí)間: 2025-3-28 08:24
Evolving Role of CRS and HIPEC: Current Indicationsgressive locoregional therapy that can prolong the life of selected patients with peritoneal metastases (PM). Initially, all sites of origin of PM were dealt with using the same prognostic variables, and the results were evaluated using the same parameters. Currently, PM secondary to various primary作者: 可耕種 時(shí)間: 2025-3-28 11:54
Role of HIPEC in the Prevention of Peritoneal Metastasis from Colorectal, Gastric and Appendiceal Caolorectal and gastric cancers. However, this treatment can be offered only to a small, select group of patients, and even in this select group, only a small proportion can be cured. Hence, prevention of peritoneal metastasis assumes importance. Currently, three approaches are being evaluated to prev作者: 中古 時(shí)間: 2025-3-28 17:13 作者: Calibrate 時(shí)間: 2025-3-28 19:12 作者: BORE 時(shí)間: 2025-3-29 02:52 作者: 小畫像 時(shí)間: 2025-3-29 03:11 作者: Assignment 時(shí)間: 2025-3-29 07:58 作者: 直言不諱 時(shí)間: 2025-3-29 13:01
Combined Resection Liver Metastases and Peritoneal Metastasesal resection of the metastatic disease has led to a significant improvement in the overall and disease-free survival both in selected patients compared to systemic chemotherapy alone which was previously the standard of care. At the same time, it is not uncommon for peritoneal metastases (PM) and li作者: geometrician 時(shí)間: 2025-3-29 15:54
Management of Complications of CRS and HIPECy its relatively high morbidity and mortality compared to other surgical procedures. It takes 3–12 months on an average for the quality of life to return to normal. With standardization of indications, better patient selection, development and implementation of perioperative care pathways and instit作者: 浸軟 時(shí)間: 2025-3-29 19:43 作者: 補(bǔ)角 時(shí)間: 2025-3-29 23:57
Surgical Management of Recurrent Epithelial Ovarian Cancer locoregional therapy comprising of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to systemic chemotherapy has produced promising results in the treatment of this condition for which there is no standard therapy and cure is almost impossible. This trea作者: bizarre 時(shí)間: 2025-3-30 05:30 作者: Judicious 時(shí)間: 2025-3-30 09:07
Pseudomyxoma Peritonei Arising from Epithelial Appendiceal Tumoursrs are the source of PMP in most cases, and even those with benign histopathological features have a propensity for peritoneal spread. PMP has a varied biological behaviour. Over the past three decades, numerous classifications have been used to stratify these tumours according to their prognosis..C作者: 排斥 時(shí)間: 2025-3-30 15:02
Intraperitoneal Chemotherapy for Gastric Cancer chemotherapy. Intraperitoneal chemotherapy has shown a benefit in the prevention of gastric PM when administered perioperatively in patients with advanced gastric cancer undergoing potentially curative surgery. Of the various modalities, hyperthermic intraperitoneal chemotherapy (HIPEC) has shown t作者: 顛簸下上 時(shí)間: 2025-3-30 17:46 作者: EXUDE 時(shí)間: 2025-3-30 23:03 作者: 他姓手中拿著 時(shí)間: 2025-3-31 04:30
